Dexamethasone is another corticosteroid that shares many characteristics with methylprednisolone. Although the number of patients with MS exacerbations being treated with IV dexamethasone is substantially smaller than that being treated with IVMP, there is some evidence that its effects are comparable when given as a short course. In many countries its cost is substantially lower than that of IVMP.

In the opinion of the Committee, it is difficult to give a recommendation in the absence of carefully performed studies, but intravenous dexamethasone may represent a less expensive alternative to treatment with intravenous methylprednisolone.